Exelixis | EXEL - Trade Debtors


Exelixis reported $286.92M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 10.58M 5.55M Dec/2025
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
Bayer EUR 14.19B 720M Dec/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Cytokinetics USD 1.81M 6.6M Sep/2025
Eisai JPY 249.06B 25B Dec/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Exelixis USD 286.92M 24.38M Dec/2025
Genmab DKK 998M 199M Jun/2025
Glaxosmithkline GBP 11.16B 3.46B Sep/2025
Incyte USD 1.02B 128.52M Dec/2025
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
MacroGenics USD 13.37M 55.86M Dec/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 184M 862M Dec/2025
Nektar Therapeutics USD 0 2.9M Sep/2024
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 8.98B 192M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sanofi EUR 397M 186.13M Dec/2025
Takeda JPY 757.92B 55.68B Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Xencor USD 29.3M 7.49M Dec/2025